Literature DB >> 1715308

Cystic fibrosis with three mutations in the cystic fibrosis transmembrane conductance regulator gene.

T Dörk1, U Wulbrand, T Richter, T Neumann, H Wolfes, B Wulf, G Maass, B Tümmler.   

Abstract

Three mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene were discovered in a pancreas-insufficient patient with cystic fibrosis (CF) who displayed an uncommon combination of almost normal chloride concentration in sweat tests and typical symptoms of gastrointestinal and pulmonary disease. The R553Q mutation was found on the maternal delta F508-CFTR gene. Codon 553 is located within a consensus motif of the ATP-binding cassette transport proteins at a less conserved position. Other members of this protein superfamily contain a glutamine instead of arginine at the homologous position, suggesting a modulating rather than disease-causing role of the R553Q mutation in CFTR. The amplification refractory mutation system did not detect the R553Q mutation in a further 65 normal, 113 delta F508, and 91 non-delta F508 CF chromosomes. The index case carried the R553X nonsense mutation on the paternal chromosome. The R553X mutation was present on a further 9 out of 86 German non-delta F508 CF chromosomes linked with the XV2c-KM19-Mp6d9-J44-GATT haplotypes 2-2-2-1-1 and 1-1-2-1-2. The location of R553X on separate haplotypes including both alleles of the intragenic GATT repeat suggests an ancient and/or multiple origins of the R553X mutations. The association of the genotype of the CFTR mutation and the clinical phenotype was assessed for the patients carrying the related genotypes delta F508/delta F508 (n = 80), delta F508/R553X (n = 9) and delta F508-R553Q/R553X (n = 1). In compound heterozygotes, the median chloride concentration in pilocarpine iontophoresis sweat tests was significantly lower than in the delta F508 homozygotes (P less than 0.01). The patient groups were significantly different with respect to the distributions of the centiles for height (P less than 0.001) and weight (P less than 0.01) as the most sensitive predictors of the course and prognosis in CF. Growth retardation was more pronounced in the compound heterozygotes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1715308     DOI: 10.1007/bf00197165

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  44 in total

1.  A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis.

Authors:  L E GIBSON; R E COOKE
Journal:  Pediatrics       Date:  1959-03       Impact factor: 7.124

2.  Sequences of Escherichia coli uvrA gene and protein reveal two potential ATP binding sites.

Authors:  I Husain; B Van Houten; D C Thomas; A Sancar
Journal:  J Biol Chem       Date:  1986-04-15       Impact factor: 5.157

3.  The nucleotide sequences of the rbsD, rbsA, and rbsC genes of Escherichia coli K12.

Authors:  A W Bell; S D Buckel; J M Groarke; J N Hope; D H Kingsley; M A Hermodson
Journal:  J Biol Chem       Date:  1986-06-15       Impact factor: 5.157

4.  Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS).

Authors:  C R Newton; A Graham; L E Heptinstall; S J Powell; C Summers; N Kalsheker; J C Smith; A F Markham
Journal:  Nucleic Acids Res       Date:  1989-04-11       Impact factor: 16.971

5.  Linkage relationships and allelic associations of the cystic fibrosis locus and four marker loci.

Authors:  J Schmidtke; M Krawczak; M Schwartz; M Alkan; M Bonduelle; E Bühler; M Chemke; T Darnedde; J Domagk; W Engel
Journal:  Hum Genet       Date:  1987-08       Impact factor: 4.132

6.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

7.  Complex alleles of the acid beta-glucosidase gene in Gaucher disease.

Authors:  T Latham; G A Grabowski; B D Theophilus; F I Smith
Journal:  Am J Hum Genet       Date:  1990-07       Impact factor: 11.025

8.  Complete nucleotide sequence and identification of membrane components of the histidine transport operon of S. typhimurium.

Authors:  C F Higgins; P D Haag; K Nikaido; F Ardeshir; G Garcia; G F Ames
Journal:  Nature       Date:  1982-08-19       Impact factor: 49.962

9.  [Cystic fibrosis: long-term treatment at a specialized centre, and its prognostic value (author's transl)].

Authors:  B Tümmler; H von der Hardt; W Müller; C Rieger
Journal:  Monatsschr Kinderheilkd       Date:  1982-03       Impact factor: 0.323

10.  One adenosine deaminase allele in a patient with severe combined immunodeficiency contains a point mutation abolishing enzyme activity.

Authors:  D Valerio; B M Dekker; M G Duyvesteyn; L van der Voorn; T M Berkvens; H van Ormondt; A J van der Eb
Journal:  EMBO J       Date:  1986-01       Impact factor: 11.598

View more
  25 in total

Review 1.  Cystic fibrosis modifier genes.

Authors:  Jane Davies; Eric Alton; Uta Griesenbach
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

2.  The novel complex allele [A238V;F508del] of the CFTR gene: clinical phenotype and possible implications for cystic fibrosis etiological therapies.

Authors:  Anna Diana; Angela Maria Polizzi; Teresa Santostasi; Luigi Ratclif; Maria Giuseppina Pantaleo; Giuseppina Leonetti; Danila Rosa Iusco; Crescenzio Gallo; Massimo Conese; Antonio Manca
Journal:  J Hum Genet       Date:  2016-02-25       Impact factor: 3.172

3.  The Irish cystic fibrosis database.

Authors:  S M Cashman; A Patino; M G Delgado; L Byrne; B Denham; M De Arce
Journal:  J Med Genet       Date:  1995-12       Impact factor: 6.318

4.  Requirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequences.

Authors:  Juan L Mendoza; André Schmidt; Qin Li; Emmanuel Nuvaga; Tyler Barrett; Robert J Bridges; Andrew P Feranchak; Chad A Brautigam; Philip J Thomas
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

5.  Three prevalent mutations in a patient with phenylalanine hydroxylase deficiency: implications for diagnosis and genetic counselling.

Authors:  P Guldberg; H L Levy; K F Henriksen; F Guttler
Journal:  J Med Genet       Date:  1996-02       Impact factor: 6.318

6.  Significance of each of three missense mutations, G484A, G667A, and G808A, present in an inactive allele of the human Lewis gene (FUT3) for alpha(1,3/1,4)fucosyltransferase inactivation.

Authors:  H Pang; Y Koda; M Soejima; H Kimura
Journal:  Glycoconj J       Date:  1998-10       Impact factor: 2.916

7.  Light and alcohol evoked electro-oculograms in cystic fibrosis.

Authors:  Paul A Constable; John G Lawrenson; Geoffrey B Arden
Journal:  Doc Ophthalmol       Date:  2006-10-05       Impact factor: 2.379

8.  A neutral variant involved in a complex CFTR allele contributes to a severe cystic fibrosis phenotype.

Authors:  Jérôme Clain; Jacqueline Lehmann-Che; Emmanuelle Girodon; Joanna Lipecka; Aleksander Edelman; Michel Goossens; Pascale Fanen
Journal:  Hum Genet       Date:  2005-03-03       Impact factor: 4.132

9.  CF2603/4delT, a new frameshift mutation in exon 13 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Authors:  B Ezquieta; J Molano
Journal:  Hum Genet       Date:  1993-07       Impact factor: 4.132

10.  Point mutations in the tyrosine aminotransferase gene in tyrosinemia type II.

Authors:  E Natt; K Kida; M Odievre; M Di Rocco; G Scherer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.